Resolution of evaluable target joints in subjects receiving prophylaxis in B-LONG/B-YOND (subanalysis 3)
| Target joints, n | 93 |
| Target joints resolved, n (%) | 93 (100.0) |
| Resolved target joints with ≥6 mo follow-up postresolution, n (%)∗ | 92 (98.9) |
| Evaluable target joints with recurrence postresolution, n (%)†,‡ | 9 (9.8) |
| Evaluable target joints without recurrence in the postresolution period, n (%)†,‡ | 83 (90.2) |
| Median (IQR) postresolution follow-up per target joint, mo | 47.4 (19.8-60.6) |
| Target joints, n | 93 |
| Target joints resolved, n (%) | 93 (100.0) |
| Resolved target joints with ≥6 mo follow-up postresolution, n (%)∗ | 92 (98.9) |
| Evaluable target joints with recurrence postresolution, n (%)†,‡ | 9 (9.8) |
| Evaluable target joints without recurrence in the postresolution period, n (%)†,‡ | 83 (90.2) |
| Median (IQR) postresolution follow-up per target joint, mo | 47.4 (19.8-60.6) |
A target joint was considered resolved if there were ≤2 spontaneous bleeds in a consecutive 12-month period in the target joint. Target joints were considered evaluable if they had ≥12 months consecutive follow-up and there had been no surgery on the target joint within the 12 months since the start of follow-up.
Percentage based on the number of resolved target joints.
Percentage is based on the number of resolved target joints with ≥6 months’ follow-up after resolution.
Recurrence is defined as ≥3 spontaneous bleeds in a single joint within any consecutive 6-month period after the target joint resolution.